CD24 Specific Neutra™ Antibody Products

CD24 (cluster of differentiation 24) is a membrane protein, which is anchored to the cell surface by a glycosyl-phosphatidyl-inositol link. It is widely expressed in various types of cells and tissues, regulating multiple downstream signal pathways and acting a crucial role in neural development. CD24 is involved with many diseases, including cancers, metabolic disorders, inflammatory and autoimmune diseases, and respiratory distress in COVID-19. Anti-CD24 monoclonal antibodies have demonstrated clinical safety and tolerability in clinical trials.

Its Gene ID: 100133941, UniProtKB ID: P25063, and OMIM ID: 600074.

CD24 Pathways

CD24 is glycosylated variably and cell type-specifically, which enables it to bind with a variety of adhesion molecules and protein ligands to perform various functions, and transduce different intracellular signals in a wide range of tissues.

The three most studied ligands of CD24 are:

Fig.1 The schematic summarizes known interactions between CD24 on tumor cells and 3 important ligands.¹

Through these interactions, CD24 is involved with pathways in intracellular calcium mobilization, protein phosphorylation, and transcription factor activation. Expression levels of CD24 are frequently high in patients with cancers, and the changed expression of CD24 will activate multiple downstream signaling pathways directly or indirectly, including Wnt/β-catenin, MAPK, PI3K/AKT-mTOR, Notch, and Hedgehog pathway.

Antibodies Targeting CD24 in Diseases

• Anti-CD24 Antibody for Cancer Therapy

CD24 is a critical positive regulator in tumor progression by activating the survival and proliferation of tumor cells. Therefore, utilizing anti-CD24 antibodies can be regarded as a promising antitumor strategy. There are several monoclonal anti-CD24 antibodies undergoing preclinical and clinical trials all over the world, for dealing with different types of malignancy, including metastatic melanoma, advanced malignant solid neoplasm, acute myeloid leukemia, colorectal cancer, breast cancer, etc.

Besides, a bispecific antibody has been recently reported to simultaneously target CD24 and CD47 to inhibit CD24/Siglec-10 and CD47/SIRPα signaling, thus significantly promoting macrophage phagocytosis to clear tumor cells, and exhibiting better effect in controlling tumor growth than either anti-CD24 or anti-CD47 monotherapy in mouse and human tumor models.

Fig.2 The functional role of CD24 in oncoimmunology.₂

• Anti-CD24 Antibody for COVID-19 Therapy

CD24 has also attracted attention as a potential target for COVID-10 therapy, because of its association with inflammatory and respiratory distress in COVID-19. There are several studies in different phases on exosomes overexpressing CD24 to deal with severe COVID-19 infection. Besides, a double-blind phase III study has been completed recently, which evaluates a protein, composed of two CD24 molecules linked to a single human IgG1 Fc. The results are encouraging that recovery time is significantly shortened, and disease progression and mortality are decreased.

Creative Biolabs offers many anti-CD24 antibody products. These antibodies are recombinantly expressed and could be used for various purposes.

REFERENCES

1. Yang, Yan, et al. "Targeting CD24 as a novel immunotherapy for solid cancers." Cell Communication and Signaling 21.1 (2023): 312.
2. Altevogt, Peter, et al. "Novel insights into the function of CD24: A driving force in cancer." International journal of cancer 148.3 (2021): 546-559.